Amkay Products Ltd
₹ 55.0
-5.01%
10 Jun
- close price
About
Incorporated in 2007, Amkay Products Ltd manufactures personalized healthcare products[1]
Key Points
- Market Cap ₹ 47.6 Cr.
- Current Price ₹ 55.0
- High / Low ₹ 82.0 / 39.2
- Stock P/E 20.6
- Book Value ₹ 30.5
- Dividend Yield 0.00 %
- ROCE 12.8 %
- ROE 9.16 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 0.68% over past five years.
- Company has a low return on equity of 13.2% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 26.41 | 40.63 | 36.47 | 27.86 | 31.07 | 38.39 | 42.03 | |
| 24.82 | 36.14 | 33.78 | 24.93 | 27.74 | 34.26 | 38.18 | |
| Operating Profit | 1.59 | 4.49 | 2.69 | 2.93 | 3.33 | 4.13 | 3.85 |
| OPM % | 6.02% | 11.05% | 7.38% | 10.52% | 10.72% | 10.76% | 9.16% |
| 0.04 | 0.10 | 0.29 | 0.46 | 1.25 | 1.32 | 0.67 | |
| Interest | 0.47 | 0.24 | 0.41 | 0.47 | 0.52 | 0.32 | 0.43 |
| Depreciation | 0.52 | 0.51 | 0.54 | 0.69 | 0.56 | 0.83 | 0.88 |
| Profit before tax | 0.64 | 3.84 | 2.03 | 2.23 | 3.50 | 4.30 | 3.21 |
| Tax % | 25.00% | 25.00% | 28.08% | 30.49% | 24.86% | 22.33% | 27.73% |
| 0.48 | 2.88 | 1.47 | 1.55 | 2.63 | 3.34 | 2.31 | |
| EPS in Rs | 173.29 | 1,039.71 | 530.69 | 559.57 | 4.13 | 3.86 | 2.67 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | 15% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -4% |
| 3 Years: | 21% |
| TTM: | -8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 25% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 13% |
| Last Year: | 9% |
Balance Sheet
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.28 | 0.28 | 0.28 | 0.28 | 6.36 | 8.66 | 8.66 |
| Reserves | 2.42 | 5.67 | 5.93 | 7.10 | 3.64 | 15.41 | 17.72 |
| 1.62 | 0.42 | 4.33 | 4.70 | 5.47 | 2.64 | 3.93 | |
| 2.55 | 7.69 | 5.26 | 2.90 | 2.47 | 3.18 | 3.00 | |
| Total Liabilities | 6.87 | 14.06 | 15.80 | 14.98 | 17.94 | 29.89 | 33.31 |
| 0.00 | 0.00 | 3.91 | 2.40 | 2.58 | 4.14 | 4.27 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 |
| Investments | 0.00 | 0.40 | 2.79 | 3.62 | 2.57 | 6.85 | 6.50 |
| 6.87 | 13.66 | 9.10 | 8.96 | 12.79 | 18.78 | 22.54 | |
| Total Assets | 6.87 | 14.06 | 15.80 | 14.98 | 17.94 | 29.89 | 33.31 |
Cash Flows
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | -0.25 | 0.01 | -0.66 | -0.32 | 1.18 | |
| 0.00 | 0.00 | -3.07 | -0.34 | 0.48 | -5.84 | -0.40 | |
| 0.00 | 0.00 | 2.59 | 0.31 | 0.24 | 7.59 | 0.86 | |
| Net Cash Flow | 0.00 | 0.00 | -0.72 | -0.01 | 0.06 | 1.43 | 1.64 |
| Free Cash Flow | 0.00 | 0.00 | -2.40 | -0.01 | -1.82 | -3.05 | 0.28 |
| CFO/OP | 0% | 0% | 10% | 32% | 7% | 17% | 54% |
Ratios
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 31.23 | 40.43 | 36.33 | 48.47 | 46.87 | 57.14 | 42.81 |
| Inventory Days | 4.54 | 4.18 | 28.03 | 46.61 | 92.57 | 112.95 | 124.73 |
| Days Payable | 41.76 | 82.57 | 64.42 | 44.46 | 33.99 | 36.44 | 28.98 |
| Cash Conversion Cycle | -5.98 | -37.96 | -0.06 | 50.62 | 105.45 | 133.65 | 138.56 |
| Working Capital Days | 10.78 | -8.62 | 21.12 | 54.11 | 56.15 | 103.92 | 96.40 |
| ROCE % | 76.33% | 28.86% | 20.87% | 22.36% | 16.88% | 12.77% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Foreign Exchange Earnings INR Lakhs |
|
||
| Number of Manufacturing Units Count |
|||
| Average Salary Increase (Non-managerial) % |
|||
| Median Remuneration Increase % |
|||
| Number of Permanent Employees Count |
|||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Audited Financial Result For The Half Year And Year Ended March 31, 2026
28 May - Audited FY26 results approved; profit fell to Rs 231.10 lakh; internal auditor reappointed for FY27.
-
Board Meeting Outcome for Outcome Of The Board Meeting
28 May - Board approved audited FY26 results and reappointed Soni Punit & Associates as internal auditor for FY27.
-
Board Meeting Intimation for Consider And Approve Audited Financial Results Of The Company For The Year Ended On March 31, 2026
20 May - Board meeting on 28 May 2026 to approve FY26 audited results and appoint internal auditor.
-
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
27 Apr - Amkay Products confirms it is not a Large Corporate under SEBI debt-fundraising norms.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
27 Apr - Amkay Products confirms it is not a Large Corporate under SEBI debt funding framework.
Business Overview:[1][2]
APL manufactures medical devices, disposables and other Healthcare Products like Face Mask, Alcohol Swabs, Lancet Needles, Nebulizer, Pulse Oximeter, Surgeon cap etc. These are used by healthcare centres, hospitals, nursing homes etc., under the brand name Amkay.
APL is the largest manufacturer of Blood Lancet Needles - Steel/Plastic in India. They have 50+ SKUs and 1000+ Distributors